Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for Belite Bio in a research note issued on Tuesday, March 3rd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.71) for the quarter, down from their previous forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $200.00 target price on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio’s Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at $4.05 EPS and FY2026 earnings at $1.89 EPS.

Several other equities analysts have also recently weighed in on BLTE. Cantor Fitzgerald raised their price target on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a report on Tuesday. Mizuho set a $223.00 target price on shares of Belite Bio in a report on Thursday, February 19th. Morgan Stanley boosted their price target on shares of Belite Bio from $191.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday. Bank of America began coverage on shares of Belite Bio in a research note on Monday, January 26th. They set a “buy” rating and a $195.00 price target on the stock. Finally, BTIG Research set a $187.00 price objective on shares of Belite Bio in a research note on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $202.33.

Belite Bio Stock Down 2.9%

Shares of Belite Bio stock opened at $172.57 on Friday. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of -75.03 and a beta of -1.46. Belite Bio has a twelve month low of $49.00 and a twelve month high of $200.00. The business has a 50-day moving average price of $169.74 and a 200-day moving average price of $124.02.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.18.

Institutional Investors Weigh In On Belite Bio

Institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC bought a new position in Belite Bio in the 2nd quarter valued at $147,000. Marshall Wace LLP purchased a new stake in shares of Belite Bio during the second quarter valued at $547,000. BNP Paribas Financial Markets bought a new position in shares of Belite Bio in the second quarter worth about $190,000. GAMMA Investing LLC increased its stake in Belite Bio by 11.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock worth $130,000 after buying an additional 176 shares during the period. Finally, High Net Worth Advisory Group LLC purchased a new position in Belite Bio in the 3rd quarter worth about $259,000. 0.53% of the stock is owned by institutional investors.

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.